Abstract
Metastatic disease is the major cause of the death in breast cancer patient (BC) cohorts. Lymph nodes, bones, lung, liver and brain are the most frequently reported sites of the metastatic disease in BC. For example, over 20% of the entire patients’ cohort suffering from aggressive metastases in the liver are individuals with primary tumours diagnosed in the breast. Further, the brain is one of the predominant sites of the metastatic disease recorded for more than 20% of some specific BC subgroups, although in BC-free populations primary brain tumours is a rare disorder. This phenomenon has not been yet adequately explained.
The achievements of our international project have substantially extended the currently existing knowledge regarding the “Seed and Soil” theory of metastasis clearly demonstrating that a strong predisposition of individuals at risk to form the systemic hypoxic pre-metastatic niches can be established a long time before the breast malignancy is clinically manifested. The Flammer syndrome (FS) phenotype may strongly contribute to the aggressive metastatic disease. The exploitation of the acquired knowledge might be performed by creating innovative screening programmes. Contextually, we propose the FS-questionnaire to be considered by family doctors (GPs) for its practical application to the general population, in order to improve the quality of primary care by developing novel more effective approaches for the targeted prevention of the metastatic BC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BC:
-
breast cancer
- BMI:
-
body mass index
- CTC:
-
circulating tumour cells
- ECM:
-
extra-cellular matrix
- FIA:
-
fibro-adenoma
- FS:
-
Flammer Syndrome
- GPs:
-
general practitioners (family doctors)
- HER-2:
-
human epidermal growth factor receptor 2
- HIF-1:
-
hypoxia-inducible factor 1
- VEGF:
-
vascular endothelial growth factor
- ТxNxМx:
-
tumour size/number of affected lymph nodes/number of metastases
References
Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V et al (2016) Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol 37(10):12941–12957. https://doi.org/10.1007/s13277-016-5168-x
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262
Golubnitschaja O, Sridhar KC (2016) Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis 33(8):743–755. https://doi.org/10.1007/s10585-016-9816-8
Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617
Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8(5):398–410
Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O (2017) Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J 8(2):119–127. https://doi.org/10.1007/s13167-017-0087-5
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA (2017) Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study. Oncologist 22(4):386–393. https://doi.org/10.1634/theoncologist.2016-0369
Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H et al (2016) Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12):e924
Chung IY, Lee JW, Lee JS, Park YR, Min YH, Lee Y et al (2017) Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. PloS One 12(3):e0170311. https://doi.org/10.1371/journal.pone.0170311
Wang J, Wang J, Li Q, Zhang P, Yuan P, Ma F et al (2017) Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts. Oncotarget 8(27):44851–44859. https://doi.org/10.18632/oncotarget.15268
Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K (2016) Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol 10(3):408–417. https://doi.org/10.1016/j.molonc.2016.01.010
Suchorska WM, Lach MS (2016) The role of exosomes in tumor progression and metastasis (Review). Oncol Rep 35(3):1237–1244. https://doi.org/10.3892/or.2015.4507
Høye AM, Erler JT (2016) Structural ECM components in the premetastatic and metastatic niche. Am J Physiol 310(11):C955–C967. https://doi.org/10.1152/ajpcell.00326.2015
Schito L, Rey S, Tafani M, Zhang H, Wong CC-L, Russo A et al (2012) Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci U S A 109(40):E2707–E2716. https://doi.org/10.1073/pnas.1214019109
Semenza GL (2016) The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta 1863(3):382–391. https://doi.org/10.1016/j.bbamcr.2015.05.036
Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91(13):1113–1124
Fidler IJ, Yano S, Zhang R-D, Fujimaki T, Bucana CD (2002) The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3(1):53–57
Rutkowski MR, Svoronos N, Perales-Puchalt A, Conejo-Garcia JR (2015) The tumor macroenvironment: cancer-promoting networks beyond tumor beds. Adv Cancer Res 128:235–262. https://doi.org/10.1016/bs.acr.2015.04.011
Chin AR, Wang SE (2016) Cancer tills the premetastatic field: mechanistic basis and clinical implications. Clin Cancer Res 22(15):3725–3733. https://doi.org/10.1158/1078-0432.CCR-16-0028
Golubnitschaja O (2017) Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J 8(1):17–22. https://doi.org/10.1007/s13167-017-0086-6
Konieczka K, Choi HJ, Koch S, Schoetzau A, Küenzi D, Kim DM (2014) Frequency of symptoms and signs of primary vascular dysregulation in Swiss and Korean populations. Klin Monatsbl Augenheilkd 231(4):344–347
Konieczka K, Fränkl S (2013) Primäre vaskuläre Dysregulation und Glaukom (Primary vascular dysregulation and glaucoma). Primäre Vaskuläre Dysregulation Glaukom Prim Vasc Dysregulation Glaucoma 34:207–215
Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring J (2016) Multiple sclerosis and primary vascular dysregulation (Flammer syndrome). EPMA J 7:13. https://doi.org/10.1186/s13167-016-0062-6
Konieczka K, Koch S, Schoetzau A, Todorova MG (2016) Increased prevalence of flammer syndrome in patients with retinitis pigmentosa. Klin Monatsbl Augenheilkd 233(4):448–452. https://doi.org/10.1055/s-0041-111802
Konieczka K, Todorova MG, Chackathayil TN, Henrich PB (2015) Cilioretinal artery occlusion in a young patient with flammer syndrome and increased retinal venous pressure. Klin Monatsbl Augenheilkd 232(4):576–578
Konieczka K, Flammer J, Sternbuch J, Binggeli T, Fraenkl S (2017) Leber’s hereditary optic neuropathy, normal tension glaucoma, and flammer syndrome: long term follow-up of a patient. Klin Monatsbl Augenheilkd 234(4):584–587. https://doi.org/10.1055/s-0042-119564
Yeghiazaryan K, Flammer J, Golubnitschaja O (2010) Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 1(2):263–272. https://doi.org/10.1007/s13167-010-0032-3
Zubor P, Gondova A, Polivka J Jr, Kasajova P, Konieczka K, Danko J et al (2017) Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach? EPMA J 8(2):129–140. https://doi.org/10.1007/s13167-017-0089-3
Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A et al (2014) Flammer syndrome. EPMA J 5(1):11. https://doi.org/10.1186/1878-5085-5-11
On the approval and implementation of medical and technological documents for standardisation of medical care of breast cancer [Internet]. Governmental Directive Number 396; Available from: http://www.moz.gov.ua/docfiles/dn_20150630_0396_ukp_dod.pdf
Golubnitschaja O, Yeghiazaryan K, Liu R, Mönkemann H, Leppert D, Schild H et al (2004) Increased expression of matrix metalloproteinases in mononuclear blood cells of normal-tension glaucoma patients. J Glaucoma 13(1):66–72
Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild HH, Berliner L (2016) Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer 16(1):357. https://doi.org/10.1186/s12885-016-2382-2
Mohan P, Antonelou M, Dadzie O, Dubrey S (2015) Headache in a young woman: leptomeningeal metastasis as the first presentation of underlying breast malignancy. BMJ Case Rep 2015:bcr2014207643. https://doi.org/10.1136/bcr-2014-207643
Manders P, Sweep FCGJ, Tjan-Heijnen VCG, Geurts-Moespot A, van Tienoven DTH, Foekens JA et al (2003) Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clin Cancer Res 9(17):6363–6370
Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C et al (2015) Clinical and translational assessment of VEGFR1 as a mediator of the premetastatic niche in high-risk localized prostate cancer. Mol Cancer Ther 14(12):2896–2900. https://doi.org/10.1158/1535-7163.MCT-15-0367
Avishai E, Yeghiazaryan K, Golubnitschaja O (2017) Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J 8(1):23–33. https://doi.org/10.1007/s13167-017-0081-y
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bubnov, R., Polivka, J., Zubor, P., Konieczka, K., Golubnitschaja, O. (2019). Relevance of Flammer Syndrome Phenotype to Metastatic Breast Cancer: Risks by Pre-metastatic Systemic Hypoxic Environment. In: Golubnitschaja, O. (eds) Flammer Syndrome. Advances in Predictive, Preventive and Personalised Medicine, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-030-13550-8_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-13550-8_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13549-2
Online ISBN: 978-3-030-13550-8
eBook Packages: MedicineMedicine (R0)